Application of curcumenol in preparation of medicine for treating triple negative breast cancer and pulmonary metastasis

By using zenol to inhibit the proliferation, migration and invasion of triple-negative breast cancer cells, the problems of recurrence and adverse reactions in existing treatment methods were solved, and effective treatment of triple-negative breast cancer and lung metastasis was achieved, and the results showed that Safety and non-toxic side effects.

CN119033759APending Publication Date: 2024-11-29LONGHUA HOSPITAL SHANGHAI UNIV OF TRADITIONAL CHINESE MEDICINE
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411103819.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-13
Publication Date
2024-11-29

AI Technical Summary

Technical Problem

At this stage, the treatment of triple-negative breast cancer has a short-term risk of recurrence and serious adverse reactions. The application of curcuminol in this type of cancer has not been reported, and effective drug selection is lacking to inhibit cancer cell proliferation, migration and invasion.

Method used

Using curcumin enol as the active ingredient, the epithelial phenotype E-cadherin and proapoptotic protein BAX, C-caspase 3, C-caspase 9 Expression inhibits the proliferation, migration, invasion and colonization capacity of triple-negative breast cancer cells, and regulates EMT and apoptosis marker proteins in tumor tissues, and prepares drugs for the treatment of triple-negative breast cancer and lung metastasis.

Benefits of technology

Curcuma enol significantly inhibited the malignant biological behavior of triple-negative breast cancer cells, prolonged tumor survival, reduced lung metastasis progression, and showed safety and no obvious toxic side effects in animal experiments.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119033759A_ABST
    Figure CN119033759A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of medicines, in particular to application of curcumenol in preparation of a medicine for treating triple negative breast cancer and pulmonary metastasis. The invention provides an effective selectable scheme for the treatment of the triple negative breast cancer. The curcumenol has an obvious inhibition effect on the proliferation ability, migration ability, invasion ability and colony ability of triple-negative breast cancer cells from different sources, has an obvious anti-tumor growth effect on triple-negative breast cancer mice, and can obviously inhibit the lung metastasis progress of triple-negative breast cancer model mice; and obvious toxic and side effects are not caused while tumors are effectively inhibited. Natural products are adopted, and medication is safe.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of medicines, and in particular to application of curcuminol in preparing medicines for treating triple-negative breast cancer and lung metastasis. Background Art

[0002] Breast cancer is a malignant tumor that seriously threatens women's health. Triple-negative breast cancer (TNBC) refers to negative expression of estrogen receptor (ER), progesterone receptor (PR), and human surface growth factor receptor 2 (HER2). It is common in women around 40 years old and accounts for about 15% to 20% of all types of breast cancer. Compared with non-triple-negative breast cancer, the pathological characteristics of this type of breast cancer are mostly invasive ductal carcinoma, and the histological grade is mostly grade III, with high recurrence and metastasis, high malignancy, and poor prognosis. Studies have shown that the median survival of metastatic TNBC is only 13 months, and the 5-year survival rate is less than 30%. At this stage, although surgery, radiotherapy, chemotherapy, and targeted therapy represented by EGFR inhibitors can improve clinical symptoms to a certain extent, they are prone to short-term recurrence risks, chemotherapy resistance, and serious adverse reactions (gastrointestinal reactions, bone marrow function suppression, hair loss, etc.).

[0003] Traditional Chinese medicine is increasingly showing its advantages in the adjuvant treatment of triple-negative breast cancer patients. It can be used in conjunction with surgery, radiotherapy, chemotherapy and other treatment methods to regulate the body's immune function, reduce the toxicity of radiotherapy and chemotherapy, prevent recurrence and metastasis, and prolong tumor-bearing survival. However, there are no reports on the relevant research on curcuminol in the treatment of breast cancer and lung metastasis. Summary of the invention

[0004] The purpose of the present invention is to provide the use of Curcumenol in preparing a medicine for treating triple-negative breast cancer and lung metastasis.

[0005] Curcumenol is the main component of Curcuma zedoaria. Previous studies have found that the natural product curcumenol can trigger ferroptosis in lung cancer cells via lncRNA H19 / miR-19b-3p / FTH1 axis and exert anti-tumor effects (Zhang R, Pan T, Xiang Y, et al. Lai-Han Leung E, Xie T, Wu Q, Sui X. Curcumenol triggeredferroptosis in lung cancer cells via lncRNA H19 / miR-19b-3p / FTH1 axis. Bioact Mater. 2021 Nov 19; 13: 23-36. doi: 10.1016 / j.bioactmat.2021.11.013.). Curcuminol combined with cisplatin can reduce the proliferation and invasion of cervical cancer cells (Mao Z, Zhong L, Zhuang X, et al. Curcumenol Targeting YWHAG Inhibits the Pentose Phosphate Pathway and Enhances Antitumor Effects of Cisplatin. Evid Based Complement Alternat Med. 2022 Jun 26; 2022: 3988916. doi: 10.1155 / 2022 / 3988916.). This compound has not been reported to be used in triple-negative breast cancer. Its molecular structure is shown in Formula 1.

[0006]

[0007] The first aspect of the present invention provides the use of curcuminol in the preparation of a drug for treating triple-negative breast cancer.

[0008] Furthermore, in the application, curcuminol is used in the preparation of a drug for inhibiting the proliferation, migration, invasion, and colonization ability of triple-negative breast cancer cells.

[0009] Furthermore, in the application, curcuminol is used in the preparation of a drug for downregulating the expression level of vimentin, a protein related to cell proliferation and invasion, and upregulating the expression level of epithelial phenotype E-cadherin, and pro-apoptotic proteins BAX, C-caspase3, and C-caspase9.

[0010] Curcumenol inhibits the malignant biological behaviors of two types of triple-negative breast cancer cells by downregulating the expression of mesenchymal phenotype N-cadherin protein and anti-apoptotic protein BCL-2, and upregulating the expression levels of epithelial phenotype E-cadherin protein, pro-apoptotic protein BAX, C-caspase 3, and C-caspase 9.

[0011] Furthermore, in the application, curcuminol is used in the preparation of a drug for resisting the tumor growth effect of triple-negative breast cancer.

[0012] Furthermore, in the application, curcuminol is used in the preparation of drugs for regulating EMT and apoptosis marker proteins in tumor tissues of triple-negative breast cancer.

[0013] Furthermore, the drug is a drug for inhibiting lung metastasis of triple-negative breast cancer.

[0014] The second aspect of the present invention provides the use of curcuminol in the preparation of a drug for inhibiting lung metastasis of triple-negative breast cancer.

[0015] The third aspect of the present invention provides a pharmaceutical preparation for treating triple-negative breast cancer and lung metastasis, wherein the active ingredient of the pharmaceutical preparation is curcuminol.

[0016] Furthermore, the pharmaceutical preparation is prepared according to the conventional preparation method of traditional Chinese medicine monomers to be clinically acceptable.

[0017] Furthermore, the pharmaceutical preparation is an injection or an oral preparation.

[0018] The advantages of the present invention are:

[0019] 1. The present invention provides an effective alternative for the treatment of triple-negative breast cancer. Curcuminol has a significant inhibitory effect on the proliferation ability, migration ability, invasion ability, and colony ability of triple-negative breast cancer cells from different sources. Curcuminol may inhibit the malignant biological behavior of triple-negative breast cancer cells by downregulating the expression of mesenchymal phenotype N-cadherin protein and anti-apoptotic protein BCL-2, and upregulating the expression levels of epithelial phenotype E-cadherin protein, pro-apoptotic protein BAX, C-caspase 3, and C-caspase 9. In animal experiments, low and high doses of curcuminol have a significant anti-tumor growth effect on triple-negative breast cancer mice, and have a significant regulatory effect on EMT and apoptosis marker proteins in tumor tissues of triple-negative breast cancer model mice. Curcuminol can significantly inhibit the progression of lung metastasis in triple-negative breast cancer model mice, and will not cause obvious toxic side effects while effectively inhibiting tumors.

[0020] 2. The present invention adopts natural products and is safe for use. BRIEF DESCRIPTION OF THE DRAWINGS

[0021] Figure 1 .Network pharmacology study of curcuminol in the treatment of triple-negative breast cancer;

[0022] Figure 2 .The effect of curcuminol on the proliferation of triple-negative breast cancer cells;

[0023] Figure 3 .The effect of curcuminol on the migration ability of triple-negative breast cancer cells;

[0024] Figure 4 .The effect of curcuminol on the invasion ability of triple-negative breast cancer cells;

[0025] Figure 5 .The effect of curcuminol on the colony formation ability of triple-negative breast cancer cells;

[0026] Figure 6 .Effects of curcuminol on the expression of EMT and apoptosis marker proteins in triple-negative breast cancer cells;

[0027] Figure 7 . Anti-tumor effect of curcuminol on triple-negative breast cancer model mice;

[0028] Figure 8 .The effect of curcuminol on the expression of EMT and apoptosis marker proteins in triple-negative breast cancer mice;

[0029] Fig. 9 .Inhibitory effect of curcuminol on lung metastasis of triple-negative breast cancer mice;

[0030] Fig.10 . Curcumenol downregulates NF-κB / TGF-β pathway to inhibit triple-negative breast cancer;

[0031] Fig.11 .Safety evaluation of curcuminol in the treatment of triple-negative breast cancer. DETAILED DESCRIPTION

[0032] The specific implementation methods provided by the present invention are described in detail below in conjunction with examples.

[0033] Example 1: Network pharmacology study of Curcumenol in the treatment of triple-negative breast cancer

[0034] The target proteins corresponding to Curcumenol were screened through the Swiss database and Super-pred database, and the gene names of the target proteins were uniformly converted through the Uniprot database, and a total of 222 gene targets of Curcumenol were obtained. A search was performed through the GeneCards database, and 6304 triple-negative breast cancer-related genes were screened, with 141 intersection targets ( Figure 1 A).

[0035] Protein interaction analysis of the intersection targets was performed using the STRING database. Targets with strong interactions were obtained through degree ranking in the PPI network, including the TP53 gene closely related to cancer development, the EGFR and ERBB2 genes and the MMPs, MAPKs, and JAKs families related to cell proliferation and invasion, and the Caspase, CCNA, and CDK genes related to cell apoptosis. Figure 1 BC).

[0036] The enrichment analysis of 141 potential targets of Curcumenol in the treatment of triple-negative breast cancer showed that its possible signaling pathways include the PI3K-Akt signaling pathway, MAPK signaling pathway, and HIF-1 signaling pathway, which are related to cancer development, invasion and metastasis. Figure 1 DE).

[0037] Example 2: Pharmacodynamic observation of Curcumenol in the treatment of triple-negative breast cancer

[0038] Based on the above results, the present invention preliminarily determined that Curcumenol can play a therapeutic role in inhibiting triple-negative breast cancer, and therefore conducted experimental studies to observe the pharmacodynamics.

[0039] 2.1 Effect of Curcumenol on the proliferation of triple-negative breast cancer cells

[0040] Take triple-negative breast cancer cells 4T1 and MDA-MB-231 in the logarithmic growth phase and adjust the cell density to 5×10 4 / mL, inoculated in 96-well cell culture plates, 6 replicates per group, set up a blank control group and different concentrations of Curcumenol groups, after 24 and 48 hours of intervention, CCK8 method was used to detect the changes in the proliferation ability of triple-negative breast cancer cells after drug intervention. The results showed that compared with the blank control group, different concentrations of Curcumenol intervention for 24 and 48 hours could significantly reduce the survival rate of 4T1 and MDA-MB-231 cells (*P<0.05, **P<0.01), and there was a dose-dependency, indicating that the drug can inhibit the proliferation ability of two triple-negative breast cancer cells ( Figure 2 ).

[0041] 2.2 Effect of Curcumenol on the migration ability of triple-negative breast cancer cells

[0042] Mouse breast cancer cells 4T1 and human breast cancer cells MDA-MB-231 in the logarithmic growth phase were inoculated into 6-well cell culture plates for cell scratching. After the cells adhered to the wall, basal culture medium or 25, 50, and 100 μM Curcumenol were added and cultured for 24 hours. Pictures were taken under an inverted microscope, and the healing area and migration rate of the scratch area were calculated. The results showed that compared with the blank control group, 50 and 100 μM Curcumenol intervention for 24 hours significantly reduced the migration rate of 4T1 and MDA-MB-231 cells (**P<0.01, *P<0.05; Figure 3 ). This indicates that Curcumenol has a significant inhibitory effect on the migration ability of triple-negative breast cancer cells from different sources.

[0043] 2.3 Effect of Curcumenol on the Invasion Ability of Triple-Negative Breast Cancer Cells

[0044] The triple-negative breast cancer cells 4T1 and MDA-MB-231 in the logarithmic growth phase were inoculated in 6-well cell culture plates, and blank control groups and different concentrations of Curcumenol (25, 50, 100 μM) were set up for intervention for 24 hours. Matrigel matrix gel was diluted with serum-free medium at a ratio of 1:5 on ice, and 50 μL per well was added to the upper chamber of the Transwell chamber. After the matrix gel was polymerized into a gel, serum-free medium was added to the upper and lower chambers for overnight hydration. The cell density was adjusted to 5×10 4 / mL, 100 μL per well was inoculated in the upper chamber of the Transwell chamber (8 μm pore size), 500 μL of culture medium containing 5% serum was added to the lower chamber, and incubated for 24 hours, with 3 replicates per group. The filter membrane was fixed and stained with crystal violet, photographed under an inverted microscope, and the cells that moved to the lower layer of the membrane were counted. Five fields of view were counted for each sample, and the average was taken.

[0045] The results showed that compared with the blank control group, 25, 50, and 100 μM Curcumenol intervention for 24 hours could significantly reduce the number of 4T1 and MDA-MB-231 cells that passed through the chamber (**P<0.01; Figure 4 ). In summary, Curcumenol can significantly inhibit the invasion ability of triple-negative breast cancer cells from different sources.

[0046] 2.4 Effect of Curcumenol on the colony formation ability of triple-negative breast cancer cells

[0047] The triple-negative breast cancer cells 4T1 and MDA-MB-231 in the logarithmic growth phase were inoculated in 6-well cell culture plates, and blank control groups and different concentrations of Curcumenol (25, 50, 100 μM) were set up for intervention for 24 hours. Then the cells in each group were digested, centrifuged, and counted. 1000 cells were plated in each 6-well plate, and the medium was changed every other day. After 14 days, the cells in each group formed different colony states. After washing twice with PBS, the cells were fixed with paraformaldehyde for 5 minutes and stained with crystal violet for 20 minutes. The number of colonies in each group was recorded by taking pictures and the average was taken.

[0048] The results showed that compared with the blank control group, after 24 hours of drug intervention, different concentrations of Curcumenol could inhibit the colony ability of 4T1 and MDA-MB-231 cells (**P<0.01, *P<0.05; Figure 5 ). In summary, Curcumenol can significantly inhibit the colony ability of triple-negative breast cancer cells from different sources.

[0049] 2.5 Effect of Curcumenol on the expression of EMT and apoptosis-related proteins in triple-negative breast cancer cells

[0050] Triple-negative breast cancer cells 4T1 and MDA-MB-231 in the logarithmic growth phase were inoculated into 6-well plates, respectively. Curcumenol (25, 50, 100 μM) was added to the cells for intervention for 24 h, and then proteins were extracted. Western-blot was used to detect the expression levels of EMT epithelial and mesenchymal phenotypes and apoptosis-related proteins.

[0051] The results showed that with the increase of dose, the regulatory effect of Curcumenol on EMT and apoptosis marker proteins of two breast cancer cells gradually increased. For 4T1 cells, 100μM concentration of Curcumenol can significantly downregulate the expression of mesenchymal phenotype N-cadherin and anti-apoptotic protein BCL-2; 50 and 100μM concentrations of Curcumenol intervention can significantly downregulate the expression level of cell proliferation and invasion-related vimentin, and upregulate the expression level of epithelial phenotype E-cadherin, pro-apoptotic protein BAX, C-caspase 3, and C-caspase 9 (**P<0.01, *P<0.05; Figure 6 AD).

[0052] For MDA-MB-231 cells, 25, 50, and 100 μM of Curcumenol can reduce the expression level of Vimentin, a protein related to cell proliferation and invasion; 50 and 100 μM of Curcumenol intervention can significantly downregulate the expression of mesenchymal phenotype N-cadherin and anti-apoptotic protein BCL-2, and upregulate the expression levels of epithelial phenotype E-cadherin and pro-apoptotic protein C-caspase 3. 100 μM of Curcumenol can upregulate the expression levels of pro-apoptotic proteins BAX and C-caspase 9 (**P<0.01, *P<0.05; Figure 6 EH).

[0053] In summary, Curcumenol may inhibit the malignant biological behaviors of two types of triple-negative breast cancer cells by downregulating the expression of mesenchymal phenotype N-cadherin protein and anti-apoptotic protein BCL-2, and upregulating the expression levels of epithelial phenotype E-cadherin protein, pro-apoptotic protein BAX, C-caspase 3, and C-caspase 9.

[0054] 2.6 Antitumor effect of Curcumenol on triple-negative breast cancer model mice

[0055] Female BALB / c mice aged 6-8 weeks were selected and injected with 4T1 triple-negative breast cancer cell suspension into the left fat pad of the second mammary gland at a cell density of 2×10 5 / mL, 0.1mL per mouse, to establish a triple-negative breast cancer mouse model. All modeling animals were randomly divided into: model control group (ip, normal saline, once every other day), low-dose Curcumenol group (ip, 5 mg / kg, once every other day), high-dose Curcumenol group (ip, 10 mg / kg, once every other day), PTX positive drug group (ip, 10 mg / kg, once a week). Tumor volume reached 100mm 3 The drug was started at the above time. During the treatment period, the growth status of the mice was observed, the tumor volume and the weight of the mice were recorded, and the long and short diameters of the tumor were measured with a vernier caliper. The tumor volume = (long diameter × short diameter × short diameter) / 2. After 3 weeks of drug administration, the mice were dissected, the tumor was completely removed, weighed, and photographed ( Figure 7 A).

[0056] The results showed that 3 days after inoculation of 4T1 triple-negative breast cancer cells, a mung bean-sized lump could be felt in the second pair of fat pads on the left side of some mice, and all of them developed tumors within 7 to 10 days. The tumor volume of mice in the model control group gradually increased over time, while the growth trend of tumor volume in mice in the low- and high-dose groups of Curcumenol significantly decreased at different time points, which was significantly different from the model control group (*P<0.05, **P<0.01; Figure 7 BD). Immunohistochemistry showed that the intervention of Curcumenol could reduce the proliferation ability of tumor tissue and promote the apoptosis of tumor tissue (**P<0.01; Figure 7 EH). In conclusion, low and high doses of Curcumenol have significant anti-tumor growth effects on triple-negative breast cancer mice.

[0057] 2.7 Effect of Curcumenol on EMT and apoptosis marker protein expression in triple-negative breast cancer model mice

[0058] The tumor tissues of each group were added to the protein lysis buffer for homogenization, and the proteins were extracted. Western-blot was used to detect the expression levels of EMT epithelial and mesenchymal phenotypes and apoptosis-related proteins, and the effects of Curcumenol on the epithelial and mesenchymal phenotypes and apoptosis levels of tumors in mice with triple-negative breast cancer were evaluated.

[0059] The results showed that compared with the model control group, low-dose and high-dose Curcumenol significantly downregulated the anti-apoptotic protein Bcl-2, mesenchymal phenotype marker protein N-cadherin, and proliferation and invasion metastasis-related protein Vimentin in tumors; and both upregulated the expression level of epithelial phenotype E-cadherin; high-dose Curcumenol could upregulate the expression levels of pro-apoptotic proteins BAX, C-caspase 9, and C-caspase 3 (*P<0.05, **P<0.01; Figure 8 ). In summary, Curcumenol has a significant regulatory effect on EMT and apoptosis marker proteins in tumor tissues of triple-negative breast cancer model mice.

[0060] 2.8 Anti-pulmonary metastasis effect of Curcumenol on triple-negative breast cancer model mice

[0061] Modeling, drug administration, and grouping were the same as above. After 3 weeks of drug intervention, the mice were killed, and the metastatic lung tissues were isolated and soaked in picric acid for 48 hours. The lung nodules were counted, and the tissues were embedded in paraffin, sectioned, and stained with hematoxylin & eosin (H&E) to observe the pathological changes of lung metastasis tissues.

[0062] The results showed that compared with the model control group, the number of lung metastatic nodules in the Curcumenol groups and the paclitaxel group was significantly reduced (*P<0.05, **P<0.01; Fig. 9 AB). HE staining results showed that the area of ​​lung metastasis in the model control group almost occupied the entire observation field (alveolar structure and inflammatory infiltration were severe), while the area of ​​lung metastasis in the high-dose Curcumenol group (10 mg / kg) and the PTX positive drug group was smaller, and the treatment effect was relatively good ( Fig. 9 C). Immunohistochemistry showed that compared with the model control group, Curcumenol could upregulate the expression level of E-cadherin, an epithelial phenotype, in lung tissue and significantly downregulate Vimentin, a protein related to proliferation, invasion and metastasis (**P<0.01; Fig. 9 DG). In conclusion, Curcumenol significantly inhibited the progression of lung metastasis in triple-negative breast cancer model mice.

[0063] 2.9 Curcumenol inhibits triple-negative breast cancer by downregulating NF-κB / TGF-β pathway

[0064] Transcriptome sequencing was used to further explore the deep mechanism of Curcumenol in inhibiting triple-negative breast cancer. The results showed that compared with the model group, Curcumenol could upregulate the expression of 200 genes (including IL7, HCAR2 and NF-κB inhibitor NF-κBID), and downregulate the expression of 289 genes (including APLNR, SLC7A11 and TGF-β which is closely related to invasion and metastasis) ( Fig.10 AB). Enrichment analysis of these differentially expressed genes revealed that Curcumenol may play a role by regulating signaling pathways such as NF-κB / TGF-β. RT-PCR and Western-Blot experiments verified that p-NF-κB and TGF-β in tumor tissues were significantly inhibited after intervention with Curcumenol. In summary, Curcumenol inhibits triple-negative breast cancer by downregulating the NF-κB / TGF-β pathway.

[0065] Example 3: Safety evaluation of Curcumenol in the treatment of triple-negative breast cancer

[0066] In order to investigate the safety of Curcumenol, pathological examinations were performed on the liver, kidney, spleen, heart, and other organs of each group of mice. Compared with the model control group injected with normal saline intraperitoneally, the low- and high-dose Curcumenol groups had no obvious pathological damage to the major organs. Fig.11 As shown, Curcumenol can effectively inhibit tumors without causing obvious toxic side effects.

[0067] In summary, the traditional Chinese medicine compounds selected in the present invention are safe, non-toxic and have no side effects, and have the advantages of significant effects.

[0068] The preferred embodiments of the present invention have been specifically described above, but the present invention is not limited to the embodiments. Those skilled in the art may make various equivalent modifications or substitutions without violating the spirit of the present invention. These equivalent modifications or substitutions are all included in the scope defined by the claims of this application.

Claims

1. Application of curcuminol in the preparation of drugs for the treatment of triple-negative breast cancer.

2. The use of curcuminol according to claim 1 in the preparation of a drug for treating triple-negative breast cancer, characterized in that: Application of curcuminol in the preparation of drugs for inhibiting proliferation, migration, invasion and colonization ability of triple-negative breast cancer cells.

3. The use of curcuminol according to claim 1 in the preparation of a drug for treating triple-negative breast cancer, characterized in that: The application of curcuminol in the preparation of drugs for downregulating the expression level of cell proliferation and invasion-related vimentin and upregulating the expression level of epithelial phenotype E-cadherin, pro-apoptotic proteins BAX, C-caspase 3 and C-caspase9.

4. The use of curcuminol according to claim 1 in the preparation of a drug for treating triple-negative breast cancer, characterized in that: Application of curcuminol in the preparation of drugs for inhibiting tumor growth of triple-negative breast cancer.

5. The use of curcuminol according to claim 1 in the preparation of a drug for treating triple-negative breast cancer, characterized in that: Application of curcuminol in the preparation of drugs for regulating EMT and apoptosis marker proteins in tumor tissues of triple-negative breast cancer.

6. The use of curcuminol according to claim 1 in the preparation of a drug for treating triple-negative breast cancer, characterized in that: The drug is a drug for inhibiting lung metastasis of triple-negative breast cancer.

7. Application of curcuminol in the preparation of drugs for inhibiting lung metastasis of triple-negative breast cancer.

8. A pharmaceutical preparation for treating triple-negative breast cancer and lung metastasis, characterized in that: The active ingredient of the pharmaceutical preparation is curcuminol.

9. The pharmaceutical preparation according to claim 8, characterized in that The pharmaceutical preparation is prepared according to the conventional preparation method of traditional Chinese medicine monomers and is clinically acceptable.

10. The pharmaceutical preparation according to claim 9, characterized in that The pharmaceutical preparation is an injection or an oral preparation.